A step closer to optimal ART for all children
- PMID: 37541703
- DOI: 10.1016/S2352-3018(23)00132-7
A step closer to optimal ART for all children
Conflict of interest statement
IJC and AT declare no competing interests. IJC has received funding grants through their institution from ViiV Healthcare, AbbVie, and Gilead, outside the submitted work. AT is a trial clinician in the ODYSSEY/Penta 20 trial (NCT02259127) and the chief investigator of the D3/Penta 21 (NCT04337450) trial; both are sponsored by Penta Foundation and funded by ViiV Healthcare.
Comment on
-
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.Lancet HIV. 2023 Aug;10(8):e506-e517. doi: 10.1016/S2352-3018(23)00107-8. Lancet HIV. 2023. PMID: 37541705 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical